Ovarian Cancer Clinical Trials

Showing 701-720 of 909 trials

Bevacizumab and Carboplatin for Patients With Ovarian Cancer

NCT00744718

This is a phase II trial to investigate the effect of bevacizumab and carboplatin in patients with platin resistant ovarian cancer.

Ovarian Cancer

Vejle Hospital73 participantsStarted Aug 2008

Vejle, Denmark

COMPLETEDPhase 1/2

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

NCT01472783

The main purpose of this study is to investigate the effect of veliparib in ovarian cancer patients with known BRCA 1/2 mutations who do no longer respond to conventional chemotherapy.

Recurrent, Epithelial Ovarian Cancer

Vejle Hospital49 participantsStarted Nov 2011

Vejle, Denmark

COMPLETED

BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer

NCT02963688

PURPOSE: To investigate the prevalence and clinical correlation of the germline BRCA 1/2 mutation in Korean patients with high grade(HG) serous and/or endometrioid epithelial ovarian cancer (EOC). PATIENTS AND METHODS: In a nationwide case-control study on EOC conducted in Korea between 2010 and 2015, 298 Korean women with HG serous and/or endometrioid EOC were tested for gBRCA 1/2 mutation, regardless of the family history. Mutation screening was performed using the Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) and Ion PGM platform according to the manufacturer's instructions. Clinical characteristics including survival outcome was assessed in gBRCAm carriers.

To Investigate the Prevalence of BRCA 1/2 Mutation Among Ovarian Cancer

Samsung Medical Center298 participantsStarted Jan 2010

UNKNOWNPhase 1/2

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

NCT01600573

This clinical trial shall clarify the efficacy and safety of pazopanib in combination with weekly topotecan in patients with platinum-resistant or intermediate platinum-sensitive recurrent epithelial ovarian cancer, fallopian and peritoneal carcinoma

Ovarian Cancer

JSehouli68 participantsStarted May 2012

Berlin, Germany

Bevacizumab and Carboplatin for Patients With Ovarian Cancer

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Related Searches

Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Pilot Study Evaluating the Oncogramme: Analysis of Response to Induction Treatment of Patients With Breast or Ovarian Cancer.

Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse

Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer

Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma

Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer

Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission

LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma

Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Total/Subtotal Colectomy in Ovarian Cancer